Voyager Therapeutics
VYGR
101 hedge funds and large institutions have $198M invested in Voyager Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 33 increasing their positions, 34 reducing their positions, and 18 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 34
1.09% less ownership
Funds ownership: 75% → 73.9% (-1.1%)
8% less funds holding
Funds holding: 110 → 101 (-9)
34% less capital invested
Capital invested by funds: $300M → $198M (-$102M)
44% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 18
89% less call options, than puts
Call options by funds: $190K | Put options by funds: $1.68M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$6.65M |
| 2 |
Morgan Stanley
New York
|
+$6.58M |
| 3 |
JP Morgan Chase
New York
|
+$2.49M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.63M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$9.27M |
| 2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$5.51M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.7M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$2.82M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.74M |
VYGR Hedge Fund Activity: Q4 2020 in Review
101 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2020, worth a combined $198M — down 34% from $300M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of VYGR and 10 opened new positions — a net loss of 8 holders — while 34 trimmed existing stakes and 33 added.
The largest buyer was Armistice Capital, adding an estimated $6.65M. The largest seller was Bank of New York Mellon, cutting an estimated $9.27M.
- 101 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2020, down from 110 in Q3 2020.
- Funds reported $198M of Voyager Therapeutics stock for Q4 2020, down 34% quarter-over-quarter.
- 10 funds opened new Voyager Therapeutics positions in Q4 2020 and 18 closed out, a net change of -8 holders.
- The largest Voyager Therapeutics buyer in Q4 2020 was Armistice Capital, an estimated $6.65M added.
- The largest Voyager Therapeutics seller in Q4 2020 was Bank of New York Mellon, an estimated $9.27M sold.
Based on aggregated 13F filings for Q4 2020.